Aegerion Pharmaceuticals and Amryt Pharma in agreement for Lojuxta therapy

04 September 2017

Gowling WLG's Life Sciences team, led by partner Patrick Duxbury and including Mathilda Davidson, Alice Stagg, James Barr and Bernardine Adkins, have assisted Aegerion Pharmaceuticals in its licensing agreement with Amryt Pharma.

Under the terms of the agreement, Amryt is granted the exclusive rights to the medical product Lojuxta hard capsules in the European Economic Area (EEA), Switzerland, Turkey and certain Middle Eastern and North African countries.

The team advised Aegerion on the complex drafting and negotiation of the transaction documents. The agreement includes an exclusive license for Amryt to promote and distribute the drug, paying Aegerion sales-related milestone payments and royalties. Amryt will also be responsible for ongoing regulatory and part-marketing obligations in support of the Lojuxta brand. 

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.

Related   Life Sciences